Journal of Oral and Maxillofacial Surgery
Volume 62, Issue 5 , Pages 527-534 , May 2004

Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases

  • Salvatore L Ruggiero, DMD, MD

      Affiliations

    • Chief, Division of Oral and Maxillofacial Surgery, Long Island Jewish Medical Center, New Hyde Park, NY, USA
    • Corresponding Author InformationAddress correspondence and reprint requests to Dr Ruggiero: Division of Oral and Maxillofacial Surgery, Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA
    • ,
  • Bhoomi Mehrotra, MBBS

      Affiliations

    • Attending, Division of Hematology and Oncology, Long Island Jewish Medical Center, New Hyde Park, NY, USA
    • ,
  • Tracey J Rosenberg, DMD, MD

      Affiliations

    • Former Chief Resident, Division of Oral and Maxillofacial Surgery, Long Island Jewish Medical Center, New Hyde Park, NY, USA
    • ,
  • Stephen L Engroff, DDS, MD

      Affiliations

    • Fellow, Department of Dentistry and Oral and Maxillofacial Surgery, University of Maryland Medical Systems, Baltimore, MD, USA

References 

  1. Hortobagyi GN, Theriualt RL, Lipton A, et al.  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J Clin Oncol. 1998;16:2038
  2. Conte PF, Giannessi PG, Latreille J, et al.  Delayed progression of bone metastases with pamidronate therapy in breast cancer patients (A randomized multicenter phase III trial). Ann Oncol. 1994;5(suppl 7):S41
  3. Rodan GA, Fleisch HA. Bisphosphonates (Mechanisms of action). J Clin Invest. 1996;97:2692
  4. Hughes DE, MacDonald BR, Russell RGG, et al.  Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest. 1989;83:1930
  5. Hughes DE, Wright KR, Uy HL, et al.  Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res. 1995;10:1478
  6. Murakami H, Takahashi N, Sasaki T, et al.  A possible mechanism of the specific action of bisphosphonates on osteoclasts (Tiludronate preferentially affects polarized osteoclasts having ruffled borders). Bone. 1995;17:137
  7. Sahni M, Guenther HL, Fleisch H, et al.  Bisphosphonates act on rat bone resorption through the mediation of oteoblasts. J Clin Invest. 1993;91:2004
  8. van Holten-Verzantvoort ATM, Kroon HM, Bijvoet OLM, et al.  Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol. 1993;11:491
  9. Berensen JR, Lichtenstein A, Porter L, et al.  Long term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol. 1998;16:593
  10. Hortobagyi GN, Theriualt RL, Porter L, et al.  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastasis. N Engl J Med. 1996;335:1785
  11. Berensen JR, Lichtenstein A, Porter L, et al.  Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. N Engl J Med. 1996;334:448
  12. Theriualt RL, Lipton A, Hortobagyi ON, et al.  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic lesions (A randomized placebo-controlled trial). J Clin Oncol. 1999;17:846
  13. Hillner BE, Ingle JN, Berenson JR, et al.  American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. J Clin Oncol. 2000;18:1378
  14. Berenson JR, Hillner BE, Kyle RA, et al.  American Society of Clinical Oncology clinical practice guidelines (The role of bisphosphonates in multiple myeloma). J Clin Oncol. 2002;20:3719
  15. Coleman RE. Optimizing treatment of bone metastases by ArediaR and ZometaR. Breast Cancer. 2000;7:361
  16. Mashiba T, Hirano T, Turner CH, et al.  Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res. 2001;5:613
  17. Brumsen C, Hamdy NA, Papapoulos SE. Long-term effects of bisphosphonates on the growing skeleton (Studies of young patients with severe osteoporosis). Medicine. 1997;76:266
  18. Glorieux FH, Bishop NJ, Plotkin H, et al.  Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N Engl J Med. 1998;339:947
  19. Whyte MP, Wenkert D, Clements KL, et al.  Bisphosphonate-induced osteopetrosis. N Engl J Med. 2003;349:457
  20. Goodship AE, Walker PC, McNally D, et al.  Use of a bisphosphonate (pamidronate) to modulate fracture repair in ovine bone. Ann Oncol. 1994;5(suppl 7):S53
  21. Cao Y, Mori S, Mashiba T, et al.  Raloxifene, estrogen and alendronate affect the processes of fracture repair differently in ovariectomized rats. J Bone Miner Res. 2002;17:2237
  22. Li J, Mori S, Kaji Y, et al.  Effect of bisphosphonate (incadronate) on fracture healing of long bones in rats. J Bone Miner Res. 1999;14:969
  23. Thiebaud HD, Sauty A, Burckhardt P, et al.  An in vitro and in vivo study of cytokines in the acute-phase response associated with bisphosphonates. Calcif Tiss Int. 1997;61:386
  24. Kapitola J, Zak J, Lacinova Z, et al.  Effect of growth hormone and pamidronate on bone blood flow, bone mineral and IGF-I levels in the rat. Physiol Res. 2000;49(suppl 1):S101
  25. Kapitola J, Zak J. Effect of pamidronate on bone blood flow in oophorectomized rats. Physiol Res. 1998;47:237
  26. Fournier P, Boissier S, Filleur S, et al.  Bisphosphonates inhibit angiogenesis in vitro and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats. Cancer Res. 2002;62:6538
  27. Santini D, Vincenzi B, Avvisati G, et al.  Pamidronate induces modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res. 2002;8:1080
  28. Wood J, Bonjean K, Ruetz S, et al.  Novel antiangiogenic effects of the bisphosphonate compound zolendronic acid. J Pharmacol Exp Ther. 2002;302:1055
  29. Powles T, Paterson S, Kanis JA, et al.  Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer. J Clin Oncol. 2002;20:3219
  30. Narai S, Nagahata S. Effects of alendronate on the removal torque of implants in rats with induced osteoporosis. Int J Oral Maxillofac Implants. 2003;18:218
  31. Starck W, Epker B. Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis (A case report). Int J Oral Maxillofac Implants. 1995;10:74
  32. Diel ID, Solomayer EF, Costa SD, et al.  Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med. 1998;339:357

PII: S0278-2391(04)00195-8

doi: 10.1016/j.joms.2004.02.004

Journal of Oral and Maxillofacial Surgery
Volume 62, Issue 5 , Pages 527-534 , May 2004

Article Tools

* Image Usage & Resolution